What can be a potential complication of tPA administration?

The administration of tissue plasminogen activator (tPA) is critical for the management of ischemic strokes, as it works to dissolve the blood clots that are blocking blood flow to the brain. However, one of the significant risks associated with tPA is hemorrhage. This complication occurs because tPA, as a thrombolytic agent, not only breaks down the clot in the brain but can also increase the risk of bleeding in other areas, including intracranial hemorrhages or other areas of the body where there might be a vulnerability.

Patients receiving tPA must be carefully monitored for signs of bleeding, and certain contraindications are considered before administration, such as recent surgeries or existing bleeding disorders. The potential for hemorrhage underscores the need for careful patient selection and monitoring in acute stroke management. Prioritizing patient safety while maximizing the potential benefits of tPA therapy is essential, making the understanding of this complication crucial for healthcare providers.